CA3147801A1 - Promedicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer - Google Patents

Promedicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer Download PDF

Info

Publication number
CA3147801A1
CA3147801A1 CA3147801A CA3147801A CA3147801A1 CA 3147801 A1 CA3147801 A1 CA 3147801A1 CA 3147801 A CA3147801 A CA 3147801A CA 3147801 A CA3147801 A CA 3147801A CA 3147801 A1 CA3147801 A1 CA 3147801A1
Authority
CA
Canada
Prior art keywords
group
compound
mmol
axitinib
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3147801A
Other languages
English (en)
Inventor
Jiasheng LU
Jiamin GU
Gang Chen
Qiguo Zhang
Chengyong SUN
Xianqi Kong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Risen Suzhou Pharma Tech Co Ltd
Original Assignee
Risen Suzhou Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910818675.XA external-priority patent/CN112442010B/zh
Priority claimed from CN201910817505.XA external-priority patent/CN112442009B/zh
Priority claimed from CN201910818779.0A external-priority patent/CN112442011B/zh
Application filed by Risen Suzhou Pharma Tech Co Ltd filed Critical Risen Suzhou Pharma Tech Co Ltd
Publication of CA3147801A1 publication Critical patent/CA3147801A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), et des sels et esters pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions pharmaceutiques de ceux-ci, utiles pour inhiber ou moduler l'activité de tyrosine kinases et traiter des affections ou des états pathologiques à médiation par des tyrosine kinases, notamment des cancers. (I)
CA3147801A 2019-08-30 2020-08-28 Promedicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer Pending CA3147801A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201910818675.XA CN112442010B (zh) 2019-08-30 2019-08-30 一类前药化合物及其在治疗癌症方面的应用
CN201910817505.X 2019-08-30
CN201910817505.XA CN112442009B (zh) 2019-08-30 2019-08-30 氘代化合物及其在治疗癌症方面的应用
CN201910818779.0 2019-08-30
CN201910818675.X 2019-08-30
CN201910818779.0A CN112442011B (zh) 2019-08-30 2019-08-30 一种前药化合物及其在治疗癌症方面的应用
US202062994364P 2020-03-25 2020-03-25
US62/994,364 2020-03-25
PCT/CA2020/051177 WO2021035360A1 (fr) 2019-08-30 2020-08-28 Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3147801A1 true CA3147801A1 (fr) 2021-03-04

Family

ID=74684795

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147801A Pending CA3147801A1 (fr) 2019-08-30 2020-08-28 Promedicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer

Country Status (5)

Country Link
EP (1) EP4021912A4 (fr)
AU (1) AU2020338490A1 (fr)
CA (1) CA3147801A1 (fr)
IL (1) IL290798A (fr)
WO (1) WO2021035360A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CN106336397A (zh) * 2015-07-07 2017-01-18 郭明山 一种作为治疗眼科疾病的新化合物
CN106317017A (zh) * 2015-07-10 2017-01-11 李建成 一种作为治疗眼科疾病的新化合物
CN106478596A (zh) * 2015-08-25 2017-03-08 李建成 一种作为治疗眼科疾病的新化合物
CA3096963A1 (fr) * 2018-04-13 2019-10-17 Hinova Pharmaceuticals Inc. Nouveau procede de synthese d'amides deuteres et de sulfonamides deuteres

Also Published As

Publication number Publication date
EP4021912A4 (fr) 2023-08-23
IL290798A (en) 2022-04-01
AU2020338490A1 (en) 2022-03-17
WO2021035360A1 (fr) 2021-03-04
EP4021912A1 (fr) 2022-07-06

Similar Documents

Publication Publication Date Title
CN106866784B (zh) 靶向线粒体抗氧化剂及其制备方法和用途
KR20120087878A (ko) 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
KR20080030079A (ko) 섬유아세포 활성 단백질 알파의 억제제
CA3084030C (fr) Composes de sulfonamide et leur utilisation
CA3104298A1 (fr) Composes de degradation/desintegration de la proteine 5 a domaine de repetition wd40 (wdr5) et methodes d'utilisation
US20210078970A1 (en) Prodrugs of the tyrosine kinase inhibitor for treating cancer
US11725020B2 (en) Prodrugs of a CDK inhibitor for treating cancers
BR112020019560A2 (pt) Moduladores de calpaína e usos terapêuticos dos mesmos
JP2018509424A (ja) 疾患を処置するためのコンジュゲート
WO2017172930A1 (fr) Conjugués de pbd pour le traitement de maladies
JPH03118394A (ja) 新規化合物、その製法及びそれを含む医薬組成物
CN110088098A (zh) 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途
JP2024014933A (ja) 関節の障害を防止又は処置するためのグルコサミン誘導体
CA3147801A1 (fr) Promedicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer
CN112442011B (zh) 一种前药化合物及其在治疗癌症方面的应用
CN111995541A (zh) 含有稳定重同位素的酰胺官能团的化合物及其应用
CN116284055A (zh) 一种kras抑制剂及其用途
AU2018387188A1 (en) Glucosamine derivatives for the prevention or treatment of joint disorders
CN112442010B (zh) 一类前药化合物及其在治疗癌症方面的应用
CN112442009B (zh) 氘代化合物及其在治疗癌症方面的应用
CN106146612B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
ES2249314T3 (es) Bisindolilmaleimidas para la inhibicion de proliferacion celular.
CA3173095A1 (fr) Isotopes lourds stables dans des groupes fonctionnels amide et utilisations correspondantes
CA3199926A1 (fr) Derives de 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide servant d'inhibiteurs de vhl pour le traitement de l'anemie
WO2023057812A1 (fr) Composés, compositions pharmaceutiques et méthodes pour le traitement, la prévention ou la gestion d'un trouble hyperprolifératif

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929